Table 6.
Studies on ablation therapy for liver metastasis from various types of primary tumors
| Author | Publication year | Type of primary tumor | Type of ablation | No. of patients | Size of tumors [mm] | Follow-up [months] | Local tumor control [%] | Overall survival [months] | Overall survival [%] | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1-year | 2-year | 3-year | 4-year | 5-year | |||||||||
| Wu et al. [42] | 2022 | Ovarian Cancer | RFA | 30 | – | – | – | 39 (median) | 93.3 | 80 | 53.3 | – | – |
| Zhao et al. [41] | 2020 | NSCLC | RFA/MWA | 21 | 24.4 (mean) | 36.4 (median) | 85.7 | 27.7 (median) | – | – | – | – | – |
| Bale et al. [39] | 2016 | Malignant melanoma | RFA | 20 | 17 (median) | – | 86.7 | 19.3 (median) | 64 | – | 41 | – | 17 |
| Jin et al. [40] | 2012 | Nasopharyngeal | RFA | 50 | – | – | 48 | 14.8 (mean) | 56 | 14 | 2 | – | – |
| RFA + CX | 44 | – | – | 63.6 | 30.6 (mean) | 91 | 61 | 36 | – | – | |||
RFA radiofrequency ablation, MWA microwave ablation